MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wort, S. J.
Right arrow Articles by Mitchell, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wort, S. J.
Right arrow Articles by Mitchell, J. A.

Vol. 62, Issue 5, 1147-1153, November 2002

Cyclooxygenase-2 Acts as an Endogenous Brake on Endothelin-1 Release by Human Pulmonary Artery Smooth Muscle Cells: Implications for Pulmonary Hypertension

Stephen J. Wort, Mandy Woods,1 Timothy D. Warner,1 Timothy W. Evans, and Jane A. Mitchell

Unit of Critical Care Medicine, Imperial College School of Medicine, Royal Brompton Hospital, London, United Kingdom

Endothelin-1 is a potent vasoconstrictor and comitogen for vascular smooth muscle. As such, it has been implicated in pulmonary vascular remodeling and in the development of pulmonary hypertension. Prostacyclin has been shown to be an effective therapy for human pulmonary hypertension, reducing morbidity and mortality, although the mechanism of its action is unknown. Here, we show that the combination of TNF-alpha and IFN-gamma induces the release of endothelin-1 from human pulmonary artery smooth muscle cells via increased transcription of prepro endothelin-1. The release of endothelin-1 and the transcription of prepro endothelin-1 mRNA were inhibited by the activity of coinduced cyclooxygenase-2. Endothelin-1 release was also inhibited by a prostacyclin-mimetic (cicaprost). Thus, under inflammatory conditions, in which vascular smooth muscle is an important source of endothelin-1, the induction of cyclooxygenase-2 represents an endogenous "braking" mechanism. In addition, the beneficial effects of prostacyclin in the treatment of pulmonary hypertension may be caused, at least in part, by the inhibition of endothelin-1 release. Finally, we suggest that these observations may help to explain why patients with pulmonary hypertension experience exacerbations after taking indomethacin and that the newly introduced selective cyclooxygenase-2 inhibitors may increase endothelin-1 production in susceptible patients, leading to vascular remodeling and the development of pulmonary hypertension.

1 Current affiliation: Department of Cardiac and Vascular Inflammation Research, William Harvey Research Institute, St Bartholomew's and the Royal London School of Medicine and Dentistry, London, UK.

Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 FASEB J.Home page
L. De Franceschi, O. S. Platt, G. Malpeli, A. Janin, A. Scarpa, C. Leboeuf, Y. Beuzard, E. Payen, and C. Brugnara
Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice
FASEB J, June 1, 2008; 22(6): 1849 - 1860.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
L. E. Fredenburgh, O. D. Liang, A. A. Macias, T. R. Polte, X. Liu, D. F. Riascos, S. W. Chung, S. L. Schissel, D. E. Ingber, S. A. Mitsialis, et al.
Absence of Cyclooxygenase-2 Exacerbates Hypoxia-Induced Pulmonary Hypertension and Enhances Contractility of Vascular Smooth Muscle Cells
Circulation, April 22, 2008; 117(16): 2114 - 2122.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
D. Merkus, B. Houweling, V. J. de Beer, Z. Everon, and D. J. Duncker
Alterations in endothelial control of the pulmonary circulation in exercising swine with secondary pulmonary hypertension after myocardial infarction
J. Physiol., May 1, 2007; 580(3): 907 - 923.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. Breuiller-Fouche, C. Moriniere, E. Dallot, S. Oger, R. Rebourcet, D. Cabrol, and M.-J. Leroy
Regulation of the Endothelin/Endothelin Receptor System by Interleukin-1{beta} in Human Myometrial Cells
Endocrinology, November 1, 2005; 146(11): 4878 - 4886.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
B. Houweling, D. Merkus, M. M. D Dekker, and D. J Duncker
Nitric oxide blunts the endothelin-mediated pulmonary vasoconstriction in exercising swine
J. Physiol., October 15, 2005; 568(2): 629 - 638.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. Woods, E. G. Wood, S. C. Bardswell, D. Bishop-Bailey, S. Barker, S. J. Wort, J. A. Mitchell, and T. D. Warner
Role for Nuclear Factor-{kappa}B and Signal Transducer and Activator of Transcription 1/Interferon Regulatory Factor-1 in Cytokine-Induced Endothelin-1 Release in Human Vascular Smooth Muscle Cells
Mol. Pharmacol., October 1, 2003; 64(4): 923 - 931.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics